Relation of β2 -Adrenoceptor Haplotype to Risk of Death and Heart Transplantation in Patients With Heart Failure

• Published in: The American journal of cardiology Vol. 99; no. 2; pp. 250 - 255
• Main Authors: Shin, Jaekyu, PharmD, Lobmeyer, Maximilian T., BS, Gong, Yan, PhD, Zineh, Issam, PharmD, Langaee, Taimour Y., PhD, Yarandi, Hossein, PhD, Schofield, Richard S., MD, Aranda, Juan M., MD, Hill, James A., MD, Pauly, Daniel F., MD, PhD, Johnson, Julie A., PharmD
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier 2007
• Subjects: Biological and medical sciences; Cardiology. Vascular system; Cardiovascular; Heart; Heart failure, cardiogenic pulmonary edema, cardiac enlargement; Medical sciences; Heart; Human; Heart failure; Cardiovascular disease; Patient; Risk; β2-Adrenergic receptor; Transplantation; Homotransplantation; Phlebology; Treatment; Heart disease; Surgery; Risk factor; Graft; Death; Circulatory system; Cardiology; Haplotype
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2006.08.020

Heart failure (HF) is characterized by neurohormonal activation of the sympathetic nervous and renin-angiotensin systems. Genetic polymorphisms in these systems could alter the prognosis in HF. We hypothesized the genetic polymorphisms in the sympathetic nervous and renin-angiotensin systems are associated with adverse outcomes, defined as death or heart transplantation in patients with HF. A total of 227 patients with HF were enrolled from a tertiary care clinic and followed for outcomes for ≤4 years. Eight polymorphisms in 6 genes were genotyped: β1 -adrenergic receptor (ADRB1, S49G, R389G), β2 -adrenergic receptor (ADRB2, G16R, Q27E), α2c -adrenergic receptor (ADRA2C, insertion/deletion 322-325), angiotensinogen (AGT, M235T), angiotensin receptor type 1 (AGTR1, 1166A>C), and angiotensin-converting enzyme (ACE, insertion/deletion in intron 16). Most patients were treated according to consensus guidelines. Male gender (hazard ratio 2.24, 95% confidence interval 1.27 to 3.94), higher New York Heart Association functional class (hazard ratio 2.54, 95% confidence interval 1.84 to 3.52), and 2 copies of ADRB2 Arg16Gln27 haplotype (hazard ratio 1.91, 95% confidence interval 1.09 to 3.36) increased the risk of adverse outcomes. In contrast, a higher serum sodium level (hazard ratio 0.91, 95% confidence interval 0.86 to 0.97) and higher creatinine clearance (hazard ratio 0.99, 95% confidence interval 0.98 to 0.99) decreased the risk of adverse outcomes. None of the other genotypes/haplotypes were associated with adverse outcomes. In conclusion, ADRB2 Arg16Gln27 haplotype may significantly increase the risk of adverse outcomes in patients with HF receiving contemporary HF pharmacotherapy.